KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Payables (2017 - 2025)

Moderna (MRNA) has disclosed Payables for 9 consecutive years, with $317.0 million as the latest value for Q4 2025.

  • Quarterly Payables fell 21.73% to $317.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $317.0 million through Dec 2025, down 21.73% year-over-year, with the annual reading at $317.0 million for FY2025, 21.73% down from the prior year.
  • Payables for Q4 2025 was $317.0 million at Moderna, up from $267.0 million in the prior quarter.
  • The five-year high for Payables was $520.0 million in Q4 2023, with the low at $8.0 million in Q1 2021.
  • Average Payables over 5 years is $280.4 million, with a median of $290.5 million recorded in 2021.
  • The sharpest move saw Payables skyrocketed 2387.5% in 2022, then plummeted 52.96% in 2024.
  • Over 5 years, Payables stood at $302.0 million in 2021, then skyrocketed by 61.26% to $487.0 million in 2022, then rose by 6.78% to $520.0 million in 2023, then fell by 22.12% to $405.0 million in 2024, then fell by 21.73% to $317.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $317.0 million, $267.0 million, and $175.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.